The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01

The GLP‐1 receptor agonist exendin‐4 has recently shown good effects in a phase II clinical trial in Parkinson's disease (PD) patients. Here, a comparison of the new GLP‐1/GIP dual receptor agonist DA5‐CH and NLY01, a 40 kDa pegylated form of exendin‐4, on motor impairments and reducing inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, MiaoJun, Xue, GuoFang, Cheng, HuiFeng, Meng, PengFei, Lian, Xia, Hölscher, Christian, Li, DongFang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413783/
https://www.ncbi.nlm.nih.gov/pubmed/34125470
http://dx.doi.org/10.1002/brb3.2231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413783/
https://www.ncbi.nlm.nih.gov/pubmed/34125470
http://dx.doi.org/10.1002/brb3.2231

Ejemplares similares